Literature DB >> 24392334

Importance of 3-D image reconstruction of spectral-domain OCT on outcome of grid laser photocoagulation for diffuse diabetic macular edema.

Avinoam Ophir1, Rana Hanna2, Michael R Martinez2.   

Abstract

AIM: To present the outcome of modified grid laser photocoagulation (GLP) in diffuse diabetic macular edema (DDME) in eyes without extrafoveal and/or vitreofoveal traction.
METHODS: Inclusion criteria for the retrospective study were DDME eyes of patients with type II diabetes mellitus that had ≥4 months of follow-up following GLP. Only one eye per patient was analyzed. Using 3-D spectral-domain optical coherence tomography (3-D SD-OCT), eyes that had either extrafoveal or vitreofoveal traction, or had been previously treated by an intravitreal medication(s) were excluded. Treated DDME eyes were divided into 4 groups: A) "Classic" DDME that involved the central macula; B) edema did not involve the macular center; C) eyes associated with central epiretinal membrane (ERM); D) DDME that was associated with macular capillary dropout ≥2 disc-diameter (DD).
RESULTS: GLP outcome in 35 DDME eyes after 4-24 (mean, 13.1±6.9) months was as follows: Group A) 18 eyes with "classic" DDME. Following one or 2 (mean, 1.2) GLP treatments, best-corrected visual acuity (BCVA) improved by 1-2 Snellen lines in 44.4% (8/18) of eyes, and worsened by 1 line in 11.1% (2/18). Central macular thickness (CMT) improved by 7%-49% (mean, 26.6%) in 77.8% (14/18) of eyes. Causes of CMT worsening (n=4) were commonly explainable, predominantly (n=3) associated with emergence of extrafoveal traction, 5-9 months post-GLP. Group B) GLP(s) in DDME that did not involve the macular center (n=6) resulted in improved BCVA by 1-2 lines in 2 eyes. However, the central macula became involved in the edema process after the GLP in 3 (50%) eyes, associated with an emergence of extrafoveal traction in one of these eyes 4 months following the GLP. Group C) GLP failed in all 5 eyes associated with central ERM. Group D) GLP was of partial benefit in 2 of 6 treated eyes with macular capillary dropout ≥2DD.
CONCLUSION: Eyes with DDME that involved the macular center were found to achieve favourable outcomes after GLP(s) during mid-term follow-up, unless complicated pre-GLP or post-GLP by vitreoretinal interface abnormalities, often extrafoveal traction or ERM, or by capillary dropout ≥2DD. Prospective studies with larger cohorts are required.

Entities:  

Keywords:  3-D spectral-domain optical coherence tomography; Evi membrane; epiretinal membrane; extrafoveal traction; grid laser; macular capillary dropout; macular edema; non-center-involved macular edema; vitreofoveal traction

Year:  2013        PMID: 24392334      PMCID: PMC3874525          DOI: 10.3980/j.issn.2222-3959.2013.06.17

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  27 in total

1.  Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.

Authors:  Masoud Soheilian; Kiumars Heidari Garfami; Alireza Ramezani; Mehdi Yaseri; Gholam A Peyman
Journal:  Retina       Date:  2012-02       Impact factor: 4.256

2.  Epiretinal pathology of diffuse diabetic macular edema associated with vitreomacular traction.

Authors:  Arnd Gandorfer; Matthias Rohleder; Sabine Grosselfinger; Christos Haritoglou; Michael Ulbig; Anselm Kampik
Journal:  Am J Ophthalmol       Date:  2005-04       Impact factor: 5.258

3.  Qualitative and quantitative OCT response of diffuse diabetic macular oedema to macular laser photocoagulation.

Authors:  R Vemala; S Koshy; S Sivaprasad
Journal:  Eye (Lond)       Date:  2011-04-15       Impact factor: 3.775

4.  Three-dimensional evaluation of vitreomacular traction and epiretinal membrane using spectral-domain optical coherence tomography.

Authors:  Hideki Koizumi; Richard F Spaide; Yale L Fisher; K Bailey Freund; James M Klancnik; Lawrence A Yannuzzi
Journal:  Am J Ophthalmol       Date:  2008-01-11       Impact factor: 5.258

5.  Use of systemic steroid after successful macular surgery in eyes with epiretinal membrane: a randomized, controlled clinical study.

Authors:  M Ritter; S Sacu; G Matt; R Dunavölgyi; W Bühl; C Prünte; U Schmidt-Erfurth
Journal:  Eye (Lond)       Date:  2011-09-02       Impact factor: 3.775

6.  Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients.

Authors:  David S Boyer; David Faber; Sunil Gupta; Sunil S Patel; Homayoun Tabandeh; Xiao-Yan Li; Charlie C Liu; Jean Lou; Scott M Whitcup
Journal:  Retina       Date:  2011-05       Impact factor: 4.256

7.  The interpretation of optical coherence tomography images of the retina.

Authors:  D S Chauhan; J Marshall
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-09       Impact factor: 4.799

8.  Pathology of human cystoid macular edema.

Authors:  M Yanoff; B S Fine; A J Brucker; R C Eagle
Journal:  Surv Ophthalmol       Date:  1984-05       Impact factor: 6.048

9.  Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema.

Authors:  Eun Jee Chung; Mi In Roh; Oh Woong Kwon; Hyoung Jun Koh
Journal:  Retina       Date:  2008 Jul-Aug       Impact factor: 4.256

10.  Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results.

Authors:  C M Lee; R J Olk
Journal:  Ophthalmology       Date:  1991-10       Impact factor: 12.079

View more
  1 in total

1.  Clinical Characteristics of Patients with Newly Diagnosed Diabetic Macular Edema in Turkey: A Real-Life Registry Study-TURK-DEM.

Authors:  Bora Eldem; Sengul Ozdek; Ali Osman Saatci; Emin Ozmert; Esat Ulay; Gulsah Nomak
Journal:  J Ophthalmol       Date:  2017-02-19       Impact factor: 1.909

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.